Callan Capital LLC Purchases 10,108 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)

Callan Capital LLC grew its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 11.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,575 shares of the company’s stock after acquiring an additional 10,108 shares during the quarter. Callan Capital LLC’s holdings in Cardiff Oncology were worth $441,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of CRDF. SG Americas Securities LLC bought a new stake in shares of Cardiff Oncology during the third quarter valued at approximately $64,000. GSA Capital Partners LLP increased its holdings in shares of Cardiff Oncology by 432.7% during the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after acquiring an additional 151,613 shares in the last quarter. MAI Capital Management increased its holdings in shares of Cardiff Oncology by 0.7% during the third quarter. MAI Capital Management now owns 663,363 shares of the company’s stock valued at $1,771,000 after acquiring an additional 4,569 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Cardiff Oncology by 11.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company’s stock valued at $324,000 after acquiring an additional 12,503 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Cardiff Oncology by 3.4% during the third quarter. State Street Corp now owns 832,652 shares of the company’s stock valued at $2,223,000 after acquiring an additional 27,628 shares in the last quarter. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Up 1.1 %

Shares of NASDAQ:CRDF opened at $4.75 on Friday. The stock has a market cap of $242.87 million, a price-to-earnings ratio of -5.05 and a beta of 1.77. Cardiff Oncology, Inc. has a 12-month low of $1.65 and a 12-month high of $6.42. The business’s 50 day moving average is $4.08 and its 200 day moving average is $3.16.

Insiders Place Their Bets

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the transaction, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 7.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Piper Sandler lifted their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. HC Wainwright cut their target price on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 8th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.